SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Direxion Shares ETF Trust - Direxion Daily MSCI South Korea Bull 3X ETF

Direxion Daily South Korea Bull 3X Shares

KORU is facing intense volatility as traders react to the cyclical nature of its heavy concentration in South Korean semiconductor giants like Samsung and SK Hynix. The community is actively debating whether the stock's recent aggressive price swings represent a sustainable bull cycle fueled by AI-driven memory chip shortages or a risky, over-leveraged trade prone to rapid technical corrections.

ProShares Trust - ProShares Bitcoin ETF

ProShares Bitcoin Strategy ETF

BITO is currently drawing significant community attention due to sharp price volatility linked to broader Bitcoin market movements and institutional accumulation, with investors heavily debating whether to hold for consistent monthly dividends or exit due to NAV decay. While some traders are aggressively adding to their positions during these dips, others remain skeptical about the ETF's long-term performance compared to spot Bitcoin products.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is facing significant selling pressure as investors react to reports of a potential multibillion-dollar equity offering aimed at funding massive AI infrastructure investments. The community remains deeply divided, with some viewing the potential dilution as a necessary step to stay competitive in the AI arms race, while others criticize the spending as wasteful and express frustration over the stock's inability to sustain upward momentum.

Zcash is a privacy-focused cryptocurrency that uses trustless zero-knowledge proofs to enable fully encrypted transactions while maintaining blockchain transparency and security. It was the first cryptocurrency to implement zero-knowledge encryption for private peer-to-peer payments, addressing the fundamental privacy gap in traditional cryptocurrencies that expose transaction details publicly.   With a fixed supply of 21 million ZEC and a halving schedule similar to Bitcoin, Zcash allows users to prove transactions are valid without revealing sensitive information like wallet balances, transaction amounts, or participant identities, making it suitable for everyday payments, long-term savings, and cross-border money transfers where financial confidentiality matters.  The protocol operates on its own blockchain currently using Proof-of-Work consensus, though it's evolving toward Proof-of-Stake through the planned "Crosslink" upgrade to enhance security, scalability, and energy efficiency. Zcash employs trustless zero-knowledge proofs (Halo) within its Orchard shielded pool to verify transactions without revealing sender, receiver, or amount information.   Users can choose between transparent public transactions and shielded private transactions through Unified Addresses, which work with both types. The network is faster and cheaper than Bitcoin, with new blocks mined every 75 seconds and transaction fees typically just a fraction of a cent. Privacy adoption has surged in 2025, with over 30% of total ZEC supply now held in fully shielded pools.  Zcash was created by a group of scientists in 2013 who initially proposed Zerocoin as a privacy extension to Bitcoin before building a standalone protocol. The ecosystem operates with a self-funded development model where block rewards support independent teams through the Zcash Community Grants Committee and a new Coinholder-Controlled Fund.

Zcash

Zcash is trending following the disclosure of a critical security vulnerability in its Orchard privacy pool that could have allowed for the creation of counterfeit tokens, sparking widespread panic selling and intense debate over the platform's long-term viability. While developers have implemented a patch, the community remains deeply divided, with many traders debating whether the risk of undetected coin issuance is a fatal flaw or a buying opportunity amidst the volatility.

Telesat Corp. engages in the provision of satellite communications and consulting services. It operates through Geostationary (GEO) and Low Earth Orbit (LEO) segments. It is a global satellite operator, providing mission-critical communications solutions to support the requirements of sophisticated satellite users throughout the world and consists of 14 geostationary satellites and the Canadian payload on Viasat-1. The company was founded in 1969 and is headquartered in Ottawa, Canada.

Telesat Corp - Ordinary Shares - Class A

Telesat is generating significant investor buzz following the successful finalization of multibillion-dollar government funding agreements, which are set to accelerate the development of its Lightspeed satellite constellation. The community is actively discussing the potential for a long-term rerating as the company transitions from legacy operations to a next-generation LEO network while navigating heavy short interest and speculative volatility.

Cumberland Pharmaceuticals, Inc. is a specialty pharmaceutical company, which focuses on the acquisition, development, and commercialization of branded prescription pharmaceutical products. Its products include Acetadote, Caldolor, Kristalose, Omeclamox, Vaprisol, Vibativ, Sancuso, Boxaban, Vasculan. Dyscorban, and RediTrex. The company was founded by A. J. Kazimi on January 7, 1999 and is headquartered in Nashville, TN.

Cumberland Pharmaceuticals Inc.

Cumberland Pharmaceuticals is currently capturing investor attention following a strategic deal with Apotex and ongoing clinical momentum for its pipeline drug, ifetroban. The community is actively discussing the stock's tight float, potential squeeze dynamics, and the high-value implications of upcoming ifetroban data for Duchenne muscular dystrophy and oncology indications.

ETF Opportunities Trust - T-Rex 2X Inverse MSTR Daily Target ETF

T-Rex 2X Inverse MSTR Daily Target ETF

MSTZ is seeing high engagement from traders capitalizing on increased volatility in MicroStrategy, with the community actively debating whether the stock's inverse leverage offers a sustainable path for profit or carries significant decay risks. Investors are heavily focused on navigating the ongoing price swings by using technical setups to scale in and out of positions while monitoring Bitcoin's broader market trends.

iShares Bitcoin Trust ETF (The) - iShares Bitcoin Trust Beneficial Interest

iShares Bitcoin ETF

IBIT is currently attracting significant attention as institutional demand surges, with BlackRock's ETF capturing the majority of recent Bitcoin inflows while BTC trends toward the $80,000 level. Investors are closely monitoring options market activity and the upcoming Clarity Act markup, fueling community debate over whether this represents the beginning of a sustained breakout or a potential trap for retail traders.

Grayscale Bitcoin Mini Trust ETF - Common units of fractional undivided beneficial interest

Grayscale Bitcoin Mini Trust ETF

The Grayscale Bitcoin Mini Trust ETF is trending as investors debate whether current market volatility and geopolitical tensions present a buying opportunity or a signal of deeper downside. Community discussion is heavily focused on the interplay between self-custody, institutional leverage, and broader macroeconomic factors impacting Bitcoin's role as a risk asset.

Solidion Technology, Inc. engages in researching, developing and manufacturing battery components and materials, batteries and related energy storage products for the automotive electric vehicle and other markets. The company was founded on June 30, 2023 and is headquartered in Dallas, TX.

Solidion Technology Inc

Solidion Technology is trending following news of patent-backed lithium battery advancements targeting aerospace and AI sectors, triggering aggressive retail interest and a potential short squeeze. Investors are actively debating the sustainability of the price action, with many monitoring for a continuation of the rally ahead of a highly anticipated industry IPO.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Definium Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Companys management team will participate in a...

Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder

Definium Therapeutics, Inc. (Nasdaq: DFTX) (Definium or the Company), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address the underlying...

Definium Therapeutics Announces New Employee Inducement Grants

Definium Therapeutics, Inc. (Definium or the Company), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric...

Definium Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

Definium Therapeutics, Inc. (Definium or the Company) (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes...

Definium Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026

Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that it will host a live webcast at 4:30 p.m. EDT on Thursday, May...

Definium Therapeutics, Inc. (NASDAQ:DFTX) Receives Consensus Recommendation of "Buy" from Analysts

Shares of Definium Therapeutics, Inc. (NASDAQ:DFTX - Get Free Report) have been given a consensus rating of "Buy" by the fifteen brokerages that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, eleven have given a buy recom...

Definium Therapeutics, Inc. (NASDAQ:DFTX) Short Interest Update

Definium Therapeutics, Inc. (NASDAQ:DFTX - Get Free Report) was the target of a large decline in short interest during the month of April. As of April 15th, there was short interest totaling 9,819,886 shares, a decline of 35.1% from the March 31st total of 15,129,638 shares. Currently, 10.1% of...

Definium Therapeutics (NASDAQ:DFTX) Stock Price Down 6.7%  - Here's What Happened

Definium Therapeutics (NASDAQ:DFTX) Shares Down 6.7% - Here's What Happened...

Q1 Earnings Estimate for DFTX Issued By HC Wainwright

Definium Therapeutics, Inc. (NASDAQ:DFTX - Free Report) - Investment analysts at HC Wainwright issued their Q1 2027 earnings estimates for shares of Definium Therapeutics in a report issued on...

Definium Therapeutics Investor Day: DT120 Phase III Readouts Set for Late Q2-Q3, PTSD Plan for 2027

Definium Therapeutics (NASDAQ:DFTX) used a company event to outline its late-stage development plans for DT120, an oral disintegrating tablet (ODT) formulation of LSD being studied for generalized anxiety disorder (GAD) and major depressive disorder (MDD), with an additional phase III study in post...

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

DFTXDefinium Therapeutics Inc.

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest DFTX News